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Introduction
The main objective of the study is to determine the safety, immunologic response, and clinical effect of vaccination with dendritic cell (DC)/breast cancer fusions administered in conjunction with IL-12 to patients with metastatic breast cancer. DC/breast carcinoma fusion cells present a broad array of tumor-associated antigens in the context of DC-mediated costimulation. In clinical studies, vaccination with fusion cells was well tolerated, induced immunologic responses in a majority of patients, and resulted in disease regression in subset. We postulated that administration of the vaccine in conjunction with IL-12 would further enhance vaccine response by promoting T cell activation. In this study, we are conducting a phase I/II clinical trial in which patients with metastatic breast cancer undergo vaccination with DC/tumor fusions administered in conjunction with rhIL-12. An initial cohort of patients was treated with the DC/tumor fusions alone. In the subsequent cohort, fusion cells are being administered with rhIL-12 given subcutaneously at the time of vaccine administration and on days 3 and 5. Measures of tumor specific cellular and humoral immunity are being obtained at serial time points following vaccination. Time to disease progression and RECIST measurable disease response will be followed as a secondary endpoint.
Clinical Trial
After completion of a review by the DOD, IRB and the FDA, patients were enrolled in the activated protocol for the generation of DC/tumor fusion vaccines. As reported in the Quarterly Reports of July 2011 through March 2012, seven patients have been enrolled thus far. We reported in detail the characterization of the tumor cells, the generated dendritic cells and the DC/tumor fusions pertaining to Patients BV01, BV03, BV04, BV05 and BV06. Patient BV07 has had her tumor collected and is being characterized at the time of writing this report. Of the seven participants enrolled (as of July 2012), three came off study prior to receiving the investigational vaccine: two had progressive disease, and one elected to pursue standard of care therapy only. Three participants, BV01, BV04 and BV06, completed vaccinations. Two patients demonstrated disease progression during the follow up period.
Since the previous updates, patient BV07 was enrolled in the study after meeting all eligibility criteria. Participant BV07 had her tumor collection on July 2 nd , 2012. Characterization of the collected tumor cells is listed in Table 1 . Preparation of the tumor-DC fusion vaccine is currently in progress.
Summary of patients processed for the study for the period of 07/01/2011 -06/30/12
Patients recruited for the study for the above period are summarized below. Table 1 lists the properties of tumor cells isolated from the patients (from pleural effusion and tissue biopsy) before and after cryopreservation. Table 2 lists the characterization of dendritic cells generated from leukapheresis collection. 
Isolation of tumor cells:
Generation of dendritic cells:
All patients listed below, underwent a single leukapheresis collection. Peripheral blood mononuclear cells (PBMCs) were isolated by Ficoll-Paque and cultured in RPMI 1640 with 1% autologous plasma for 1-2 h to select the adherent cell population. Nonadherent cells were removed, and the adherent population of cells was cultured in complete RPMI 1640 containing 1% autologous sera. The yields and viability of the cells following leukapheresis and the generation of dendritic cells (and phenotypic surface markers) are listed in Table 2 . Tumor cells and DCs were combined at a ratio of 1:7 and washed in serum-free medium. After low-speed centrifugation, the cell pellets were resuspended in 500 μl of 50% polyethylene glycol in Dulbecco's PBS without Ca 2+ and Mg 2+ , washed free of polyethylene glycol, and cultured in RPMI 1640 with 10% autologous plasma and 500 IU/ml GM-CSF. DC, tumor cells and fusion cells were stained with primary murine monoclonal antibodies against MUC1, Cytokeratin CAM, HLA-DR, CD54, or CD86 and an isotype-matched negative control for 60 min. The cells were incubated with a biotinylated F(ab′) 2 fragment of horse antimouse IgG for 45 min and incubated for 30 min with avidin biotin complex reagent solutions followed by 3 amino-9-ethyl carbazole solution. Detection of MUC1, CAM, or cytokeratin with the avidin-biotin complex reagents was followed by staining for other markers with the avidin-biotin complex-alkaline phosphatase kit. For patient BV04, tumor cells were shown to strongly express cytokeratin, CAM and MUC1 and did not express CD86. Tumor cells from patient BV05 strongly expressed DR and CT. For patient BV06, analysis of the pleural effusion tumor cells showed >20% of cells strongly expressing cytokeratin and MUC1 (grade 4+), whereas tumor cells from tissue biopsy showed >75% of the cells intensely positive for cytokeratin and MUC1. DCs generated from all study patients strongly expressed CD86, HLA-DR, and CD11C and did not express cytokeratin, CAM or MUC1 (Table 2) . Fusions generated for patients for the period of 07/01/2011 -06/30/12 are summarized in Table 3 . The fusion viability, together with fusion efficiency and the total number of doses prepared are listed in Table 3 . Doses are based on the number of viable fusion cells (as assessed by trypan blue exclusion) that coexpress DC-and tumor-associated markers (see below). An adequate yield of fusion cells and the absence of contamination as assessed by assays for sterility, endotoxin, and Mycoplasma were completed prior to vaccination. 
Patient #
Generation of DC/tumor fusions and fusion dose:
Patient #
Immune monitoring:
For patient BV01, vaccination resulted in the expansion of breast cancer reactive T cells as manifested by the percent of CD4 and CD8+ T cells expressing IFNγ following ex vivo exposure to autologous tumor lysate. Furthermore, weak responses to PHA and Tetanus Toxoid were observed post vaccination; whereas, no significant change was observed in the levels of regulatory T cells or those that expressed FOXP3 pre-and post-vaccination. Immunologic monitoring of the other treated patients is ongoing.
